Lung Cancer Trials Ask AI to find trials
RecruitingPhase 1 / Phase 2NCT07278479
Official study title

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

Study summary

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[212Pb\]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3 positive tumors.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studied[212Pb]Pb-MP0712 and [203Pb]Pb-MP0712

The study team can explain what participation involves.

Who it may be forSmall cell lung cancer (SCLC) · Locally advanced · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 21, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Phase 1 / Phase 2

Interventional

Where is it offered?8 U.S. locations

Locations may change over time.

Who runs it?Molecular Partners AG

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1 / Phase 2
Sponsor
Molecular Partners AG
Interventions being studied
Drug: [212Pb]Pb-MP0712; Other: [203Pb]Pb-MP0712
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Small cell lung cancer (SCLC)→
Disease setting
Locally advanced→Metastatic or stage IV→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Key
  • Age ≥ 18 years old
  • Histologically or cytologically confirmed: I. advanced extensive or limited SCLC or LC NECs of the lung
  • SCLC (extensive stage, or limited stage) patients with progression or recurrence following at least two prior line of systemic platinum based therapy and immunotherapy or are not suitable or tolerating the standard of care treatment as second line of systemic therapy, or
  • LC NEC of the lung patients with progression or recurrence following at least one prior line of systemic therapy, or II. epNECs with progression or recurrence following at least one prior line of systemic therapy:
  • Gastroenteropancreatic NECs (GEPNEC), or
  • Cervical NECs, or
  • Bladder NECs, or
  • other epNECs with previously confirmed DLL3 expression by IHC.
  • Patients with prior DLL3-targeted therapy are allowed.
  • For epNECs in Part 1 and Part 2 and SCLC or LC NECs of the lung in Part 2: DLL3-positivity by \[203Pb\]Pb-DOTAM-MAM279 SPECT/CT
  • Radiographically documented disease progression or recurrence during or after the last line of systemic treatment therapy
  • At least one measurable disease per RECIST v1.1.
  • Adequate bone marrow reserve and organ function as demonstrated by complete blood count, and biochemistry in blood and urine at Screening
  • Adequate blood counts: Hemoglobin ≥9 g/dL; Absolute neutrophil count (ANC) ≥1.5 × 10\^9/L; Platelets ≥100 × 10\^9/L; White blood cells (WBC) ≥2.5 x 10\^9/L;
  • Adequate hepatic function
  • Adequate renal function: Calculated glomerular filtration rate (GFR) \>60mL/min (using Cockroft-Gault formula).
  • Patients with known central nervous system (CNS) metastasis will be eligible if they are clinically stable. Key
Reasons someone may not be able to joinExclusion criteria
  • Uncontrolled intercurrent illness
  • Patients who have not had resolution of all clinically significant toxic effects of prior systemic cancer therapy, surgery, or radiotherapy to Grade ≤1 (except for grade ≤2 alopecia, or stable grade 2 sensory neuropathy, according to the last CTCAE version).
  • Active clinically significant cardiac disease
  • Evidence of interstitial lung disease or active, non-infectious pneumonitis.
  • History of other malignancy within the past 2 years with exceptions. Other protocol-defined inclusion/

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Moffitt Cancer CenterTampa, Florida
  • Emory University HospitalAtlanta, Georgia
  • University of ChicagoChicago, Illinois
  • United TheranosticsGlen Burnie, Maryland
  • Nebraska Cancer SpecialistsOmaha, Nebraska
  • United TheranosticsPrinceton, New Jersey
  • University Hospitals Cleveland Medical CenterCleveland, Ohio
  • The University of Texas MD Anderson Cancer CenterHouston, Texas

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 21, 2026. Always confirm current availability with the study team.

View original record ↗